|

Product Information
Clinic Support
Client Information
Technical Information
|
Directions for the Use of
Therapeutic Allergenic Extracts — Package Insert
Diagnosis
The diagnosis of allergy consists of a thorough examination,
correlated with a carefully taken history, and evaluation of
appropriate differential diagnoses. The definitive diagnosis is
supported by in vitro (ELISA) tests for allergen-specific IgE or
in vivo tests (intradermal skin tests), the results of which are
used in the formulation of immunotherapy. In immediate type
hypersensitivity in the dog and cat, the skin is most frequently
the target tissue. Occasionally, the cat may show respiratory
signs. When allergy occurs, the clinical manifestations are
that of atopic dermatitis (local or generalized), urticaria,
otitis, blepharitis and rarely asthma.
Therapy
ALLERCEPT® Allergy Treatment Sets are indicated as an aid in
alleviating symptoms associated with allergic disease in the
dog and cat. Other factors in the management of the allergic
animal include environmental control and elimination of the
offending allergens when possible.
Therapeutic Contraindications
Only those allergens to which the animal has shown
reactivity, using in vitro or in vivo tests, should be included
in the immunotherapy treatment set because of the potential
for de novo sensitization. Test results should always be
evaluated with attention to clinical signs, history and
differential diagnoses.
Sources of Allergens
Allergenic extracts are water soluble allergens derived from
natural substances that have been aseptically filtered and
preserved with phenol.
Pollen Allergens
Pollens are shed naturally from wind-pollinating plants.
Common seasonal peaks are: spring—tree pollen; late
spring through early summer—grass pollens; late summer
through fall—weed pollens (ragweeds).
Mold Allergens
Fungi (molds) are ubiquitous in the environment. Some
genera, such as Alternaria and Cladosporium, may have
seasonal peaks. Fungi are also found indoors growing on
a host of substances and may cause perennial symptoms.
Dust Mite Allergens
Dust mites are a very important perennial source of allergen.
They are found in bedding, carpeting and upholstery.
Suggested Dosage Schedules for Immunotherapy
Successful immunotherapy is accomplished by subcutaneous
injection of therapeutic allergens in increasing dosages until
the maximum tolerated dose is determined. This level is
suggested by increased pruritus, which may last for several
hours after injection. Once this level is achieved, the patient
should be kept on a maintenance dosage schedule. Thus, a
fixed treatment schedule for each animal must be established
during the course of therapy.
The schedule is provided as a general guide. For each
animal, dosage should be individualized based upon the
sensitivity to the allergens injected and continually monitored
by the response to immunotherapy. A schedule of treatment
must be determined by a veterinarian for each animal.
Immunotherapy is administered by subcutaneous injection
using a 1.0 ml sterile tuberculin syringe, with a 3/8 to
1/2-inch, 25 to 27-gauge needle. It is important to avoid
injecting into a blood vessel. Insert the needle subcutaneously,
then pull back gently on the syringe plunger prior to injection
and note if blood enters the syringe. If blood is observed, the
needle should be repositioned and checked again for blood
before injecting.
If history or response to treatment indicate a patient is
extremely sensitive, a more dilute solution may be used
initially with gradually increasing doses similar to the
suggested dosage schedule. It is recommended that dosages
less concentrated than the purchased strengths be made by
appropriate 1:10 dilutions with phenol saline.
Suggested Dosage Schedules
Vial #1 INITIAL SERIES
| Injection Number |
Days Between Injection |
Dosage (ml) |
| 1 |
— |
0.1 |
| 2 |
4 days |
0.2 |
| 3 |
4 days |
0.4 |
| 4 |
4 days |
0.8 |
| 5 |
4 days |
1.0 |
After the initial series, begin the maintenance series outlined
on the next page. Small dogs (i.e., those weighing less than
10 lbs.) and cats may be at greater risk to experience
serious reactions at higher dosages. Proceed with caution
in these cases.
Vial #2 MAINTENANCE SERIES
| Injection Number |
Days Between Injection |
Dosage (ml) |
| 6 |
4 days |
0.2 |
| 7 |
4 days |
0.4 |
| 8 |
4 days |
0.6 |
| 9 |
4 days |
0.8 |
| 10 |
4 days |
1.0 |
| 11 |
7 days |
1.0 |
| 12* |
7 to 21 days |
1.0 |
| 12+* |
7 to 21 days |
1.0 |
Order refill vials 30 days before needed.
* The dose and interval between allergy treatment injections in pets with
atopic dermatitis should be tailored according to the animal’s response.
Local Reactions
It is not unusual for the animal to experience temporary
discomfort at the time of the injection with some soreness
occurring later. A small area of swelling may occur at the site
of injection. These reactions may be decreased by massaging
the injection site(s) thoroughly following injection, decreasing
the dosage, or administering the dosage at two or more sites.
Systemic Reactions
Adverse reactions are rarely seen and usually consist of an
increase in pruritus. However, animals should always be
observed for at least 30 minutes after injection. A patient
experiencing a more serious systemic reaction may exhibit
hives, angioedema (swelling around the face and head),
restlessness, vomiting or diarrhea, and in severe anaphylaxis,
circulatory collapse and pulmonary edema. If this type of
reaction occurs, immediate veterinary attention is required.
In the event of a severe systemic reaction, administering
epinephrine 1:10,000; a fast-acting, water-soluble
corticosteroid injection such as hydrocortisone, prednisolone
or dexamethasone in a sodium phosphate or sodium
succinate base; and an injectable antihistamine such as
diphenhydramine, may be necessary.
Subsequent therapeutic doses should be reduced to the
dose that did not elicit a reaction or in case of a serious
anaphylactic reaction to a 10-fold dilution. Subsequent
doses should be increased more slowly, (i.e., use of
intermediate dilutions or repetitions of the same dose).
If, after reduction of dosage, reactions continue to occur,
corticosteroids may be given simultaneously.
Precautions
- Store Allergenic Extracts between 35° and 45° F (2° – 8° C).
- Always use a new sterile syringe and needle for each
injection.
- Do not inject intravenously. Pull back gently on syringe
plunger and note if blood enters the syringe. If blood is
obtained, the positioning of the needle should be changed
before injecting.
- Observe the animal for signs of a systemic reaction
for at least 30 minutes following administration of the
immunotherapy injection.
Caution: Due to reduced potency over time, it is recommended
that the first injection from a refill vial be administered at
one half of the previous maintenance dose.
Warning: As with any injectable, take precautions to prevent
self-administration. Allergic people should be especially
cautious as these are soluble allergens and can cause allergic
reactions when injected. Should human injection occur,
consult your physician immediately.
Clinical Response
Studies suggest that 60 – 80% of atopic dogs and cats will
benefit from this form of therapy.1-3 In general, atopic animals
require lifetime administration. If the patient has not improved
after 6 to 12 months of maintenance injections, treatment
should be re-evaluated. For a professional veterinary
consultation, call 1-800-GO HESKA (800-464-3752).
Refill Vials
Over time the potency of the allergens in a treatment set
decreases. When you receive a new refill vial, it is at full
potency. To allow your pet to adjust to the new vial, give your
pet one half of its maintenance volume for the first injection
from the refill vial. Resume full maintenance volume on
subsequent injections if no untoward reactions are seen.
References
- Allergic Skin Diseases of Dogs and Cats. Reedy LM, Miller
WH Jr and Willemse T; W.B. Saunders Company,
Philadelphia, 1998.
- Current Veterinary Dermatology. Griffin CE, Kwochka KW,
and MacDonald JM; Mosby Year Book, St. Louis, 1993.
- Small Animal Dermatology. Scott DW, Miller WH Jr. and
Griffin CE; Saunders Company, Philadelphia, 2001.
|